Related Experiment Video
Updated: May 24, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Hypertrophic cardiomyopathy with longevity to 90 years or older
Barry J Maron1, Susan A Casey, Tammy S Haas
1Hypertrophic Cardiomyopathy Center, Minneapolis Heart Institute Foundation, Minnesota, USA. hcm.maron@mhif.org
Insights
Hypertrophic cardiomyopathy (HC) patients can live to advanced age, often unrecognized until late in life. This condition is compatible with long-term survival, with death typically unrelated to HC itself.
Area of Science:
- Cardiology
- Genetics
- Geriatrics
Background:
- Hypertrophic cardiomyopathy (HC) is a primary cause of sudden cardiac death in young individuals.
- Survival into advanced age for HC patients is less understood.
- This study investigates the characteristics of elderly HC patients.
Purpose of the Study:
- To determine the prevalence, clinical features, and demographics of patients with hypertrophic cardiomyopathy surviving to 90 years or older.
- To understand the natural history and long-term outcomes of HC in the very elderly.
Main Methods:
- Retrospective analysis of 1,297 HC patients from the Hypertrophic Cardiomyopathy Center database.
- Identification of patients aged ≥90 years.
- Review of clinical data, diagnosis timing, echocardiographic findings, and causes of death.
Main Results:
- 2.0% of HC patients (26 individuals) reached ≥90 years, predominantly women (69%).
- Diagnosis often occurred late (mean age 80), incidentally or due to symptoms.
- While complications occurred in 50%, HC was not the primary cause of death; survival to the 10th decade was common.
Conclusions:
- Hypertrophic cardiomyopathy can be asymptomatic or unrecognized until advanced age.
- HC is compatible with survival into the 10th decade with minimal HC-related interventions.
- Demise in elderly HC patients is often unrelated to the cardiomyopathy, offering reassurance.
Abstract:
Hypertrophic cardiomyopathy (HC) is the most common cause of sudden death in the young, but survival to particularly advanced age is less well appreciated. The investigators report the prevalence, clinical features, and demographics of patients with HC surviving to ≥90 years of age. Of 1,297 patients with HC in the Hypertrophic Cardiomyopathy Center database (Minneapolis Heart Institute Foundation), 26 (2.0%) were identified who had achieved the age of ≥90 years; 18 (69%) were women. HC diagnosis came late in life, at 61 to 92 years (mean 80 ± 8; ≥75 years in 21 patients), recognized fortuitously by the detection of a heart murmur or during family screening (n = 6) or after onset of new symptoms (n = 20). At most recent evaluation (or death) patients were aged 90 to 96.7 years (mean 92.2 ± 2), with 6 presently alive at 91 to 96 years of age; HC did not appear to be the primary cause of death in any patient. Left ventricular wall thicknesses were 15 to 31 mm (mean 20 ± 3); 8 patients (31%) had obstruction to left ventricular outflow at rest (peak instantaneous gradients, 38 to 135 mm Hg). Significant HC-related complications occurred in 13 patients (50%), including progressive heart failure symptoms, atrial fibrillation, and nonfatal embolic stroke. Although no patient died suddenly, 13 (50%) nevertheless carried conventional HC risk markers. A greater proportion of cohort patients reached ≥90 years of age (2.0%) than expected in the general population (0.8%) (p <0.001). In conclusion, HC may be unrecognized until late in life and is consistent with survival to particularly advanced age into the 10th decade of life without the need for major HC-related treatment interventions, and with demise ultimately largely unrelated to this disease. This principle regarding the natural history of HC can afford a measure of reassurance to many patients.
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy II: Dilated Cardiomyopathy
Heart Failure II: Pathophysiology
Huntington Disease l: Introduction

